文献速递药物相互作用药物不良反应与药物警戒

FDA批准肿瘤靶向共价抑制剂与可逆抑制剂的临床药理学比较分析

A Comparative Clinical Pharmacology Analysis of FDA-Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology.
PubMed 文献 · Clin Pharmacol Ther · 2024-07-28

本文综述比较了近10年FDA批准的肿瘤靶向共价抑制剂(TCI)与可逆抑制剂(RI)的临床药理学特征。结果显示TCI的PK半衰期通常更短,按推荐剂量摩尔非结合稳态AUCss更低但临床缓解持续时间更长;TCI并未显示更优的安全性,且DDI perpetrator特征与RI相似。

要点

  • TCI的PK半衰期通常比RI短。
  • 按推荐剂量TCI的摩尔非结合AUCss低于RI,但临床缓解持续时间更长。
  • TCI与RI的安全性和DDI perpetrator特征无显著差异。

核心结论

  • TCI在临床药理学比较中至少实现了理论预测的四项临床获益中的两项。

研究设计与样本

  • 综述比较了近10年FDA批准的肿瘤TCI与RI的PK、疗效、安全性和DDI数据。

主要发现

  • TCI的PK半衰期通常更短。
  • 按各自药品标签推荐临床剂量,TCI的摩尔非结合稳态AUCss低于RI,但临床观察到的缓解持续时间更长。
  • 无 conclusive 证据支持TCI临床安全性更优。
  • TCI与RI的DDI perpetrator特征相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted covalent inhibitors (TCIs) are an emerging class of anticancer therapeutics. TCIs are designed to selectively engage their targeted proteins via covalent warheads. From the drug development standpoint, the covalent inhibition mechanism is anticipated to elicit the following theoretical benefits: (i) an extended duration of therapeutic action that is determined by the target protein turnover rate and not necessarily by drug half-life, (ii) a lower therapeutic dose owing to greater pharmacological potency, (iii) lower risk of off-target binding and associated adverse events, and (iv) reduced drug-drug interaction (DDI) liability due to high selectivity and low dose. Elucidating the clinical relevance of these expected benefits requires an integrated assessment of pharmacokinetics (PK), efficacy, safety, and DDI data. In this review, we compared the clinical pharmacology attributes of FDA-approved oncology TCIs within the last 10 years against their reversible inhibitor (RI) counterparts. Our findings indicated that (i) PK half-lives of TCIs were typically shorter and (ii) at their respective recommended clinical doses per drug label, the molar unbound steady state areas under the concentration-time curve (AUCss) of TCIs were lower than those of RIs, but with longer clinically observed durations of response. However, (iii) there was no conclusive evidence supporting improved clinical safety profiles for TCIs, and (iv) DDI perpetrator profiles appeared to be similar between TCIs and RIs. The overall clinical pharmacology comparison of TCI vs. RI surveyed in this paper suggested that at least two of the four forecasted clinical benefits were achieved by TCIs.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ngo HX, Wen YW, Pisupati S, et al. A Comparative Clinical Pharmacology Analysis of FDA-Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology. Clin Pharmacol Ther. 2024. PMID: 39072721. doi:10.1002/cpt.3390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。